Shareholders Equity and Capital Stock (Details 3) |
9 Months Ended |
|---|---|
|
Sep. 30, 2020
USD ($)
shares
| |
| Number of unvested units | shares | 872,045 |
| Remaining life (years) | 10 months 24 days |
| Aggregate Intrinsic Value | $ | $ 418,581 |
| December 14, 2020 [Member] | |
| Number of unvested units | shares | 204,636 |
| Remaining life (years) | 2 months 12 days |
| Aggregate Intrinsic Value | $ | $ 98,225 |
| November 05, 2021 [Member] | |
| Number of unvested units | shares | 667,409 |
| Remaining life (years) | 1 year 1 month 6 days |
| Aggregate Intrinsic Value | $ | $ 320,356 |
| X | ||||||||||
- Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|